hollywindler

CARDIFF-BY-THE-SEA, Calif., Feb. 5, 2026 /PRNewswire/ -- Field Medical, Inc., a clinical-stage medical technology company advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias, today announced the presentation of late breaking clinical trial data from the first-in-human Field PULSE study at the 31st Annual International AF Symposium 2026, held February 5–7 in Boston. Read the full press release here .

Field Medical announced that its founder, Steven Mickelsen, MD, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, in San Francisco. The presentation will provide a company overview and highlight progress across the FieldForce™ PFA platform, including ventricular tachycardia and atrial fibrillation programs. Read the full press release here .

Results from the first-in-human Ventricular Catheter Ablation Study (VCAS) evaluating Field Medical’s FieldForce™ Ablation System have been published in Circulation. The peer-reviewed article reports six-month outcomes demonstrating 82% freedom from VT/VF recurrence or ICD therapy and a 98% reduction in ventricular arrhythmia burden, marking an important clinical milestone in pulsed field ablation for ventricular tachycardia. Read the full press release here .